PNMA2

Across TCGA pan-cancer cohorts, PNMA2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PNMA2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PNMA2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PNMA2 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where PNMA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PNMA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+1.839	<.001	12	view →
LSCC	Female	II,III,IV	−1.700	<.001	8	view →
PDAC	All	All	+0.562	.004	4	view →
LUAD	Female	All	+0.421	.004	2	view →
HNSC	Male	II,III,IV	−0.299	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PNMA2–CCRCC

Open the CCRCC breakdown →